Cadila Healthcare, an innovation-driven global healthcare company has entered into an exclusive agreement for the technology know-how for varicella vaccine production in the Russian Federation with Pharm Aid headquartered in Russia.

The exclusive agreement was signed at the BIOTECHMED conference in Gelendzhik, Russia. Pharm Aid, has been set up by Nacimbio together with Ishvan Pharmaceuticals, for the localization of innovative vaccine production in Russia.
 
''We welcome this opportunity to participate in and partner biotech opportunities in the Russian Federation market. In Pharm Aid and Nacimbio, we have found a reliable partner, representing one of the largest state corporations. As an innovation-driven global healthcare player our aim has always been to bridge unmet healthcare needs by improving accessibility to preventives and novel therapies. By being a technology enabler, I believe we are taking yet another important step in realising this mission,'' said Sharvil Patel, Managing Director, Zydus Cadila.

Shares of the company declined Rs 1.15, or 0.24%, to trade at Rs 485.40. The total volume of shares traded was 40,780 at the BSE (2.28 p.m., Tuesday).